Clinical-Grade Plasmalogens

MLD is developing clinical-grade synthetic plasmalogen therapies for the treatment of Rhizomelic Chondrodysplasia Punctata, alzheimer’s disease, multiple sclerosis, parkinson’s and other neurological conditions*

*MLD’s plasmalogen drugs are currently undergoing required formal regulatory safety and efficacy studies and are not currently available to the public.

Peroxisomal Disorders

Rhizomelic Chondrodysplasia Punctata (RCDP) affects fewer than 100 patients in North America. but there is #hopeforRCDP and other plasmalogen-deficient peroxisomal disorders with a first-in-class vinyl-ether plasmalogen therapy under development

Neurological Conditions

Plasmalogen deficiency is associated with several neurological conditions including alzheimer’s disease, parkinson’s disease, and multiple sclerosis. Therapeutically augmenting plasmalogens represents a new paradigm for the management of these diseases.